Centocor launches online talk show on rheumatoid arthritis

Share this article:
Centocor launches online talk show on rheumatoid arthritis
Centocor launches online talk show on rheumatoid arthritis
From the people who brought you the disease awareness documentary comes New Way RA, an online talk show for people with rheumatoid arthritis hosted by Inside Edition anchor Deborah Norville.

The unbranded show, produced by Remicade maker Centocor Ortho Biotech, features five segments covering general information about the disease, diet, exercise, relationship and career advice. Altogether, the segments come to about 50 minutes and are housed at www.NewWayRA.com.

In addition to Norville, who was 10 when her mother was diagnosed with the disease, the 50 minute-long show features interviews with: Food Network host and registered dietician Ellie Krieger; Dr. W. Hayes Wilson, chief of rheumatology at Piedmont Hospital in Atlanta; Laurie Ferguson, PhD of advocacy group Creaky Joints, who speaks about the impact of RA on relationships; “chronic illness coach” Rosalind Joffe; and certified fitness instructor Ellen Shmueli, who was diagnosed with RA at age 28.

The Johnson & Johnson unit drew on insights garnered from patients, company research and RA bloggers, and the bloggers will be a key audience for the site, said Centocor PR. The company hasn't yet decided whether to produce further episodes of the show, but there are plenty more topics to cover, said a spokesperson.

The show's guests were reimbursed for travel expenses to attend the program taping, as was Dr. Wilson. Norville, Krieger and Joffe were paid for participating in the taping, the company said.   

In addition to Remicade, which is indicated for RA as well as Crohn's and other inflammatory conditions, Centocor Ortho Biotech makes Simponi, which won FDA approval in April for indications including moderately to severely active RA.

In 2007, Centocor produced Innerstate, an innovative hourlong unbranded documentary looking at the lives of three people suffering from immune-mediated inflammatory diseases.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...